Digital Biomarkers Market - Global Outlook & Forecast 2024-2029
상품코드:1426142
리서치사:Arizton Advisory & Intelligence
발행일:2024년 02월
페이지 정보:영문 352 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 디지털 바이오마커 시장 규모는 2023년에 24억 9,000만 달러에 달하며, 2023-2029년 22.86%의 CAGR로 성장할 것으로 예측되고 있습니다.
디지털화된 가상 임상연구의 부상은 원격 모니터링 기술의 발전과 보다 효율적이고 환자 중심적인 임상시험의 필요성에 힘입어 세계 디지털 바이오마커 시장에서 중요한 트렌드로 부상하고 있습니다. 이러한 추세는 환자 참여와 실제 데이터 수집을 촉진하고 다양한 헬스케어 분야에서 디지털 바이오마커의 개발 및 검증을 가속화하고 있습니다.
세계 디지털 바이오마커 시장에서 눈에 띄는 트렌드는 벤더 간 제휴와 파트너십이 증가하고 있다는 점입니다. 이러한 파트너십은 전문 지식, 기술 및 자원을 결합하여 혁신을 촉진하고 다양한 의료 분야에서 디지털 바이오마커의 적용을 확대하여 궁극적으로 환자와 의료 시스템에 이익을 가져다 줄 수 있습니다.
고령화와 만성질환 증가는 시장 성장에 매우 중요한 촉진제가 되고 있습니다. 노인 인구 증가와 만성질환의 확산으로 원격 모니터링, 조기 발견, 개인화된 헬스케어를 가능하게 하는 디지털 솔루션에 대한 수요가 증가함에 따라 디지털 바이오마커는 현대 의료에 필수적인 요소로 자리 잡고 있습니다.
디지털 바이오마커를 통한 원격 환자 모니터링의 발전은 환자 데이터를 실시간으로 제공하고, 조기 개입을 강화하며, 만성질환 관리를 최적화함으로써 헬스케어에 혁명을 일으키고 있습니다. 이러한 기술 중심의 변화는 보다 개인화되고 효율적이며 비용 효율적인 헬스케어 솔루션을 제공하기 위해 세계 디지털 바이오마커 시장의 성장을 가속하고 있습니다.
세계의 디지털 바이오마커 시장에 대해 조사했으며, 시장의 개요와 제품 유형별, 용도별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.
목차
제1장 조사 대상·조사 범위
제2장 중요 인사이트
제3장 시장의 개요
제4장 서론
제5장 시장 기회와 동향
제6장 시장 성장의 촉진요인
고령화 인구의 증가와 만성질환의 이환율
원격 환자 모니터링의 진보
디지털 헬스 문화의 성장과 외래 케어로의 이동
무선 및 웨어러블 디지털 모니터링 기술의 이용이 확대
제7장 시장 억제요인
데이터 보안과 프라이버시에 관한 우려
낮은 도입률
규제 표준화의 결여
제8장 시장 구도
시장 개요
시장 규모와 예측
Five forces 분석
제9장 제품 유형
시장 스냅숏과 성장 촉진요인
시장 개요
웨어러블과 센서
모바일 애플리케이션과 소프트웨어
제10장 용도
시장 스냅숏과 성장 촉진요인
시장 개요
심장병
호흡기과
신경과
기타
제11장 임상 실천
시장 스냅숏과 성장 촉진요인
시장 개요
진단
감시
예후
예방
기타
제12장 최종사용자
시장 스냅숏과 성장 촉진요인
시장 개요
헬스케어 기업
의료기관
기타
제13장 지역
제14장 북미
제15장 유럽
제16장 아시아태평양
제17장 라틴아메리카
제18장 중동 및 아프리카
제19장 경쟁 구도
경쟁의 개요
시장 점유율 분석
제20장 주요 기업 개요
ACTIGRAPH
ALIVECOR
AMGEN
BIOGEN
KONEKSA HEALTH
제21장 기타 유명 벤더
ADHERIUM
AURAL ANALYTICS
BIOFOURMIS
CLARIO
EMPATICA
FEEL THERAPEUTICS
GERO.AI
IXICO
OBVIO HEALTH
OWKIN
PRECORDIOR
RESAPP HEALTH
ROCKLEY PHOTONICS
SONDE HEALTH
VIVOSENSE
제22장 리포트의 개요
제23장 정량적 개요
제24장 부록
KSA
영문 목차
영문목차
The global digital biomarkers market was valued at USD 2.49 billion in 2023 and is expected to grow at a CAGR of 22.86% from 2023 to 2029.
MARKET TRENDS & DRIVERS
Rise in Digitized Virtual Clinical Research
The rise in digitized virtual clinical research is a significant trend in the global digital biomarkers market, driven by advances in remote monitoring technologies and the need for more efficient, patient-centric clinical trials. This trend allows for greater patient participation and real-world data collection, accelerating the development and validation of digital biomarkers for various healthcare applications.
Increasing Focus on Drug Development Using Digital Biomarkers
The global digital biomarkers market is witnessing a notable trend with an increasing focus on drug development. Pharmaceutical and biotech companies are leveraging digital biomarkers to enhance clinical trials, improve patient recruitment, and expedite the development of new therapies, harnessing the power of real-time data for evidence-based decision-making. This trend represents a significant shift towards more efficient and data-driven drug development processes, benefiting patients and the pharmaceutical industry.
Expanding Applications of Digital Biomarkers in Mental Health
The digital markers are increasingly used to monitor and analyze behavioral patterns, providing valuable insights into stress levels, mood fluctuations, and sleep quality, supporting the proactive management of mental health conditions. This trend reflects the broader shift towards personalized, data-driven mental healthcare.
Growing Collaborations & Partnerships Among Vendors
A prominent trend in the global digital biomarkers market is the increasing number of vendor collaborations and partnerships. These partnerships combine expertise, technologies, and resources, fostering innovation and expanding the application of digital biomarkers across various healthcare sectors, ultimately benefiting patients and healthcare systems.
Rise in Aging Population & Prevalence of Chronic Diseases
The aging population and the increasing prevalence of chronic diseases have become pivotal drivers of the market. As the elderly demographic expands and chronic conditions become more widespread, there is a growing need for digital solutions that enable remote monitoring, early detection, and personalized health management, making digital biomarkers an essential component of modern healthcare.
Advancements in Remote Patient Monitoring
Advancements in remote patient monitoring, enabled by digital biomarkers, are revolutionizing healthcare by providing real-time patient data, enhancing early intervention, and optimizing chronic disease management. This technology-driven shift is fueling the growth of the global digital biomarkers market as it offers more personalized, efficient, and cost-effective healthcare solutions.
Growing Culture of Digital Health & Shift Toward Outpatient Care
The growing culture of digital health is fostering a shift toward outpatient care, where patients can monitor and manage their health remotely. This shift is a driving force behind the global digital biomarkers market, as digital biomarkers enable real-time patient monitoring and data-driven healthcare, improving outcomes and reducing the burden on traditional healthcare facilities.
SEGMENTATION INSIGHTS
INSIGHTS BY PRODUCT TYPE
The global digital biomarkers market by product type is segmented into wearables & sensors and mobile applications & software. The wearables & sensors segment dominated the segmental share in 2023 and is expected to register the highest segmental CAGR in the global digital biomarkers market during the forecast period. Wearable devices include smartwatches, fitness trackers, and other sensor-equipped devices that collect continuous health data, such as heart rate, activity levels, and sleep patterns. Wearables are a primary source of physiological data, providing insights into various health parameters. They are crucial in remote patient monitoring, clinical trials, and preventive healthcare. Sensors measure biomarkers in bodily fluids, offering insights into various health conditions. They find applications in diagnostics, disease monitoring, and research studies.
Mobile and software applications designed for smartphones and tablets enable users to monitor and manage their health. These systems often incorporate wearable devices and sensors to collect continuous patient vital signs and health status data. They support the management of chronic diseases and post-operative care. They contribute to disease management and wellness initiatives.
Segmentation by Product Type
Wearables & Sensors
Mobile Application & Software
INSIGHTS BY APPLICATION
The global digital biomarkers market by application is segmented into cardiology, pulmonology, and neurology. In 2023, cardiology accounted for a significant segmental share of the global market, followed by pulmonology, neurology, and others. Cardiology has witnessed significant advancements, leading to a better understanding of cardiovascular diseases (CVDs) and improved diagnostic and treatment options. Digital biomarkers have recently emerged as a revolutionary tool transforming the cardiology landscape. Digital biomarkers are measurable, physiological, behavioral, or molecular data that can be collected and analyzed using digital health technologies. These biomarkers offer new ways to diagnose, monitor, and treat CVDs, ultimately improving patient outcomes and enhancing healthcare efficiency.
Segmentation by Application
Cardiology
Pulmonology
Neurology
Others
INSIGHTS BY CLINICAL PRACTICE
The diagnostic clinical practice segment held the most prominent share of the global digital biomarkers market, accounting for over 34% in 2023. Diagnostic digital biomarkers are increasingly utilized to identify specific diseases, disorders, or physiological conditions through digital data analysis. This could involve patterns in biometric data, imaging, or other digital health inputs. Monitoring digital biomarkers involves the real-time or periodic assessment of digital data to track changes in health status, disease progression, or treatment response. Wearable devices and continuous monitoring platforms are often used. Predictive digital biomarkers help anticipate specific health events, guiding preventive measures or interventions. Predictive digital biomarkers are valuable in identifying at-risk populations.
Segmentation by Clinical Practice
Diagnostic
Monitoring
Prognostic
Predictive
Others
INSIGHTS BY END-USERS
The global digital biomarkers market by end-user is segmented into healthcare companies, healthcare providers, and others. The healthcare companies segment held the most significant global market share in 2023. In the modern era of healthcare, integrating technology and data-driven solutions has revolutionized patient care, disease management, and drug development. Digital biomarkers, a novel concept in the field of healthcare, have gained prominence as a valuable tool for monitoring and diagnosing various medical conditions. Healthcare companies, including pharmaceutical firms and health tech startups, are increasingly recognizing the potential of digital biomarkers to improve patient outcomes and reduce costs. Another significant advantage of digital biomarkers is their potential to reduce healthcare costs. By adopting digital monitoring tools, healthcare companies can decrease the need for frequent in-person visits and hospital admissions.
Segmentation by End-users
Healthcare Companies
Healthcare Providers
Others
GEOGRAPHICAL ANALYSIS
North America dominated the global digital biomarkers market share, accounting for over 46% in 2023. The market in North America is witnessing remarkable growth and innovation, driven by advancements in technology, a growing emphasis on personalized healthcare, and the increasing adoption of wearable devices and digital health solutions. Factors such as an aging population, increasing healthcare costs, and a shift towards value-based care have driven the adoption of digital biomarkers. Additionally, the COVID-19 pandemic accelerated the acceptance of remote monitoring and telehealth, further boosting the industry's growth.
Segmentation by Geography
North America
The U.S.
Canada
Europe
Germany
The U.K.
France
Italy
Spain
Russia
Netherlands
APAC
Japan
China
India
South Korea
Australia
Latin America
Brazil
Mexico
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
South Africa
VENDOR LANDSCAPE
The global digital biomarkers market is experiencing rapid growth, revolutionizing the healthcare industry by incorporating technology to collect, analyze, and interpret various digital health data. As vendors strive to develop more accurate and effective digital biomarkers, healthcare professionals gain access to advanced tools for diagnosing and managing multiple medical conditions. Ultimately, this contributes to improved patient outcomes and a more efficient healthcare system. Data privacy and security have become paramount with the increasing amount of personal health data collected. Companies that can offer robust security measures and maintain the trust of their users will have a competitive edge.
Key Company Profiles
ActiGraph
AliveCor
Amgen
Biogen
Koneksa Health
Other Prominent Vendors
Adherium
Aural Analytics
Biofourmis
Clario
Empatica
Feel Therapeutics
Gero.ai
IXICO
Obvio Health
Owkin
Precordior
ResApp Health
Rockley Photonics
Sonde Health
VivoSense
KEY QUESTIONS ANSWERED:
1. How big is the digital biomarkers market?
2. What is the growth rate of the global digital biomarkers market?
3. Which region dominates the global digital biomarkers market share?
4. What are the significant trends in the digital biomarkers industry?
5. Who are the key players in the global digital biomarkers market?
TABLE OF CONTENTS
1 SCOPE & COVERAGE
1.1. MARKET DEFINITION
1.1.1. INCLUSIONS
1.1.2. EXCLUSIONS
1.1.3. MARKET ESTIMATION CAVEATS
1.2. MARKET BY SEGMENTATION
1.2.1. MARKET BY PRODUCT TYPE
1.2.2. MARKET BY APPLICATION
1.2.3. MARKET BY CLINICAL PRACTICE
1.2.4. MARKET BY END-USER
1.2.5. MARKET SEGMENTATIONS COVERED
1.2.6. REGIONS & COUNTRIES COVERED
1.2.7. BASE YEAR
1.3. MARKET DERIVATION
2 PREMIUM INSIGHTS
2.1 OPPORTUNITY POCKETS
2.2 MARKET OPPORTUNITY BY GEOGRAPHY
2.3 MARKET OPPORTUNITY BY PRODUCT TYPE
2.4 MARKET OPPORTUNITY BY APPLICATION
2.5 MARKET OPPORTUNITY BY CLINICAL PRACTICE
2.6 MARKET OPPORTUNITY BY END-USER
2.7 OVERVIEW
2.8 GEOGRAPHY INSIGHTS
2.9 PRODUCT INSIGHTS
2.10 APPLICATION INSIGHTS
2.11 CLINICAL PRACTICE INSIGHTS
2.12 END-USER INSIGHTS
3 MARKET AT A GLANCE
4 INTRODUCTION
4.1 OVERVIEW
5 MARKET OPPORTUNITIES & TRENDS
5.1 RISE IN DIGITIZED VIRTUAL CLINICAL RESEARCH
5.2 INCREASING FOCUS ON DRUG DEVELOPMENT USING DIGITAL BIOMARKERS
5.3 EXPANDING APPLICATIONS OF DIGITAL BIOMARKERS IN MENTAL HEALTH
5.4 GROWING COLLABORATIONS & PARTNERSHIPS AMONG VENDORS
6 MARKET GROWTH ENABLERS
6.1 RISE IN AGING POPULATION & PREVALENCE OF CHRONIC DISEASES
6.2 ADVANCES IN REMOTE PATIENT MONITORING
6.3 GROWING CULTURE OF DIGITAL HEALTH & SHIFT TOWARD OUTPATIENT CARE
6.4 GROWING USE OF WIRELESS & WEARABLE DIGITAL MONITORING TECHNOLOGIES
7 MARKET RESTRAINTS
7.1 DATA SECURITY & PRIVACY CONCERN
7.2 LOW ADOPTION RATE
7.3 LACK OF REGULATORY STANDARDIZATION
8 MARKET LANDSCAPE
8.1 MARKET OVERVIEW
8.2 MARKET SIZE & FORECAST
8.3 FIVE FORCES ANALYSIS
8.3.1 THREAT OF NEW ENTRANTS
8.3.2 BARGAINING POWER OF SUPPLIERS
8.3.3 BARGAINING POWER OF BUYERS
8.3.4 THREAT OF SUBSTITUTES
8.3.5 COMPETITIVE RIVALRY
9 PRODUCT TYPE
9.1 MARKET SNAPSHOT & GROWTH ENGINE
9.2 MARKET OVERVIEW
9.3 WEARABLES & SENSORS
9.3.1 MARKET OVERVIEW
9.3.2 MARKET SIZE & FORECAST
9.3.3 WEARABLES & SENSORS MARKET BY GEOGRAPHY
9.4 MOBILE APPLICATION & SOFTWARE
9.4.1 MARKET OVERVIEW
9.4.2 MARKET SIZE & FORECAST
9.4.3 MOBILE APPLICATION & SOFTWARE MARKET BY GEOGRAPHY
10 APPLICATION
10.1 MARKET SNAPSHOT & GROWTH ENGINE
10.2 MARKET OVERVIEW
10.3 CARDIOLOGY
10.3.1 MARKET OVERVIEW
10.3.2 MARKET SIZE & FORECAST
10.3.3 CARDIOLOGY MARKET BY GEOGRAPHY
10.4 PULMONOLOGY
10.4.1 MARKET OVERVIEW
10.4.2 MARKET SIZE & FORECAST
10.4.3 PULMONOLOGY MARKET BY GEOGRAPHY
10.5 NEUROLOGY
10.5.1 MARKET OVERVIEW
10.5.2 MARKET SIZE & FORECAST
10.5.3 NEUROLOGY MARKET BY GEOGRAPHY
10.6 OTHER
10.6.1 MARKET OVERVIEW
10.6.2 MARKET SIZE & FORECAST
10.6.3 OTHER MARKET BY GEOGRAPHY
11 CLINICAL PRACTICE
11.1 MARKET SNAPSHOT & GROWTH ENGINE
11.2 MARKET OVERVIEW
11.3 DIAGNOSTIC
11.3.1 MARKET OVERVIEW
11.3.2 MARKET SIZE & FORECAST
11.3.3 DIAGNOSTIC MARKET BY GEOGRAPHY
11.4 MONITORING
11.4.1 MARKET OVERVIEW
11.4.2 MARKET SIZE & FORECAST
11.4.3 MONITORING MARKET BY GEOGRAPHY
11.5 PROGNOSTIC
11.5.1 MARKET OVERVIEW
11.5.2 MARKET SIZE & FORECAST
11.5.3 PROGNOSTIC MARKET BY GEOGRAPHY
11.6 PREDICTIVE
11.6.1 MARKET OVERVIEW
11.6.2 MARKET SIZE & FORECAST
11.6.3 PREDICTIVE MARKET BY GEOGRAPHY
11.7 OTHER
11.7.1 MARKET OVERVIEW
11.7.2 MARKET SIZE & FORECAST
11.7.3 OTHER MARKET BY GEOGRAPHY
12 END-USER
12.1 MARKET SNAPSHOT & GROWTH ENGINE
12.2 MARKET OVERVIEW
12.3 HEALTHCARE COMPANIES
12.3.1 MARKET OVERVIEW
12.3.2 MARKET SIZE & FORECAST
12.3.3 HEALTHCARE COMPANIES MARKET BY GEOGRAPHY
12.4 HEALTHCARE PROVIDERS
12.4.1 MARKET OVERVIEW
12.4.2 MARKET SIZE & FORECAST
12.4.3 HEALTHCARE PROVIDERS MARKET BY GEOGRAPHY
12.5 OTHER
12.5.1 MARKET OVERVIEW
12.5.2 MARKET SIZE & FORECAST
12.5.3 OTHER MARKET BY GEOGRAPHY
13 GEOGRAPHY
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 GEOGRAPHIC OVERVIEW
14 NORTH AMERICA
14.1 MARKET OVERVIEW
14.2 MARKET SIZE & FORECAST
14.2.1 NORTH AMERICA MARKET BY PRODUCT TYPE
14.2.2 NORTH AMERICA MARKET BY APPLICATION
14.2.3 NORTH AMERICA MARKET BY CLINICAL PRACTICE
14.2.4 NORTH AMERICA MARKET BY END-USER
14.3 KEY COUNTRIES
14.4 US: MARKET SIZE & FORECAST
14.5 CANADA: MARKET SIZE & FORECAST
15 EUROPE
15.1 MARKET OVERVIEW
15.2 MARKET SIZE & FORECAST
15.2.1 EUROPE MARKET BY PRODUCT TYPE
15.2.2 EUROPE MARKET BY APPLICATION
15.2.3 EUROPE MARKET BY CLINICAL PRACTICE
15.2.4 EUROPE MARKET BY END-USER
15.3 KEY COUNTRIES
15.4 GERMANY: MARKET SIZE & FORECAST
15.5 UK: MARKET SIZE & FORECAST
15.6 FRANCE: MARKET SIZE & FORECAST
15.7 ITALY: MARKET SIZE & FORECAST
15.8 SPAIN: MARKET SIZE & FORECAST
15.9 RUSSIA: MARKET SIZE & FORECAST
15.10 NETHERLANDS: MARKET SIZE & FORECAST
16 APAC
16.1 MARKET OVERVIEW
16.2 MARKET SIZE & FORECAST
16.2.1 APAC MARKET BY PRODUCT TYPE
16.2.2 APAC MARKET BY APPLICATION
16.2.3 APAC MARKET BY CLINICAL PRACTICE
16.2.4 APAC MARKET BY END-USER
16.3 KEY COUNTRIES
16.4 JAPAN: MARKET SIZE & FORECAST
16.5 CHINA: MARKET SIZE & FORECAST
16.6 INDIA: MARKET SIZE & FORECAST
16.7 SOUTH KOREA: MARKET SIZE & FORECAST
16.8 AUSTRALIA: MARKET SIZE & FORECAST
17 LATIN AMERICA
17.1 MARKET OVERVIEW
17.2 MARKET SIZE & FORECAST
17.2.1 LATIN AMERICA MARKET BY PRODUCT TYPE
17.2.2 LATIN AMERICA MARKET BY APPLICATION
17.2.3 LATIN AMERICA MARKET BY CLINICAL PRACTICE
17.2.4 LATIN AMERICA MARKET BY END-USER
17.3 KEY COUNTRIES
17.4 BRAZIL: MARKET SIZE & FORECAST
17.5 MEXICO: MARKET SIZE & FORECAST
17.6 ARGENTINA: MARKET SIZE & FORECAST
17.7 COLOMBIA: MARKET SIZE & FORECAST
18 MIDDLE EAST & AFRICA
18.1 MARKET OVERVIEW
18.2 MARKET SIZE & FORECAST
18.2.1 MIDDLE EAST & AFRICA MARKET BY PRODUCT TYPE
18.2.2 MIDDLE EAST & AFRICA MARKET BY APPLICATION
18.2.3 MIDDLE EAST & AFRICA MARKET BY CLINICAL PRACTICE
18.2.4 MIDDLE EAST & AFRICA MARKET BY END-USER
18.3 KEY COUNTRIES
18.4 TURKEY: MARKET SIZE & FORECAST
18.5 SAUDI ARABIA: MARKET SIZE & FORECAST
18.6 UAE: MARKET SIZE & FORECAST
18.7 SOUTH AFRICA: MARKET SIZE & FORECAST
19 COMPETITIVE LANDSCAPE
19.1 COMPETITION OVERVIEW
19.2 MARKET SHARE ANALYSIS
19.2.1 ACTIGRAPH
19.2.2 ALIVECOR
19.2.3 AMGEN
19.2.4 BIOGEN
19.2.5 KONEKSA HEALTH
20 KEY COMPANY PROFILES
20.1 ACTIGRAPH
20.1.1 BUSINESS OVERVIEW
20.1.2 PRODUCT OFFERINGS
20.1.3 KEY STRATEGIES
20.1.4 KEY STRENGTHS
20.1.5 KEY OPPORTUNITIES
20.2 ALIVECOR
20.2.1 BUSINESS OVERVIEW
20.2.2 PRODUCT OFFERINGS
20.2.3 KEY STRATEGIES
20.2.4 KEY STRENGTHS
20.2.5 KEY OPPORTUNITIES
20.3 AMGEN
20.3.1 BUSINESS OVERVIEW
20.3.2 PRODUCT OFFERINGS
20.3.3 KEY STRATEGIES
20.3.4 KEY STRENGTHS
20.3.5 KEY OPPORTUNITIES
20.4 BIOGEN
20.4.1 BUSINESS OVERVIEW
20.4.2 PRODUCT OFFERINGS
20.4.3 KEY STRATEGIES
20.4.4 KEY STRENGTHS
20.4.5 KEY OPPORTUNITIES
20.5 KONEKSA HEALTH
20.5.1 BUSINESS OVERVIEW
20.5.2 PRODUCT OFFERINGS
20.5.3 KEY STRATEGIES
20.5.4 KEY STRENGTHS
20.5.5 KEY OPPORTUNITIES
21 OTHER PROMINENT VENDORS
21.1 ADHERIUM
21.1.1 BUSINESS OVERVIEW
21.1.2 PRODUCT OFFERINGS
21.2 AURAL ANALYTICS
21.2.1 BUSINESS OVERVIEW
21.2.2 PRODUCT OFFERINGS
21.3 BIOFOURMIS
21.3.1 BUSINESS OVERVIEW
21.3.2 PRODUCT OFFERINGS
21.4 CLARIO
21.4.1 BUSINESS OVERVIEW
21.4.2 PRODUCT OFFERINGS
21.5 EMPATICA
21.5.1 BUSINESS OVERVIEW
21.5.2 PRODUCT OFFERINGS
21.6 FEEL THERAPEUTICS
21.6.1 BUSINESS OVERVIEW
21.6.2 PRODUCT OFFERINGS
21.7 GERO.AI
21.7.1 BUSINESS OVERVIEW
21.7.2 PRODUCT OFFERINGS
21.8 IXICO
21.8.1 BUSINESS OVERVIEW
21.8.2 PRODUCT OFFERINGS
21.9 OBVIO HEALTH
21.9.1 BUSINESS OVERVIEW
21.9.2 PRODUCT OFFERINGS
21.10 OWKIN
21.10.1 BUSINESS OVERVIEW
21.10.2 PRODUCT OFFERINGS
21.11 PRECORDIOR
21.11.1 BUSINESS OVERVIEW
21.11.2 PRODUCT OFFERINGS
21.12 RESAPP HEALTH
21.12.1 BUSINESS OVERVIEW
21.12.2 PRODUCT OFFERINGS
21.13 ROCKLEY PHOTONICS
21.13.1 BUSINESS OVERVIEW
21.13.2 PRODUCT OFFERINGS
21.14 SONDE HEALTH
21.14.1 BUSINESS OVERVIEW
21.14.2 PRODUCT OFFERINGS
21.15 VIVOSENSE
21.15.1 BUSINESS OVERVIEW
21.15.2 PRODUCT OFFERINGS
22 REPORT SUMMARY
22.1 KEY TAKEAWAYS
22.2 STRATEGIC RECOMMENDATIONS
23 QUANTITATIVE SUMMARY
23.1 MARKET BY PRODUCT TYPE
23.1.1 NORTH AMERICA MARKET BY PRODUCT TYPE
23.1.2 EUROPE MARKET BY PRODUCT TYPE
23.1.3 APAC MARKET BY PRODUCT TYPE
23.1.4 LATIN AMERICA MARKET BY PRODUCT TYPE
23.1.5 MIDDLE EAST & AFRICA MARKET BY PRODUCT TYPE
23.2 MARKET BY APPLICATION
23.2.1 NORTH AMERICA MARKET BY APPLICATION
23.2.2 EUROPE MARKET BY APPLICATION
23.2.3 APAC MARKET BY APPLICATION
23.2.4 LATIN AMERICA MARKET BY APPLICATION
23.2.5 MIDDLE EAST & AFRICA MARKET BY APPLICATION
23.3 MARKET BY CLINICAL PRACTICE
23.3.1 NORTH AMERICA MARKET BY CLINICAL PRACTICE
23.3.2 EUROPE MARKET BY CLINICAL PRACTICE
23.3.3 APAC MARKET BY CLINICAL PRACTICE
23.3.4 LATIN AMERICA MARKET BY CLINICAL PRACTICE
23.3.5 MIDDLE EAST & AFRICA MARKET BY CLINICAL PRACTICE
23.4 MARKET BY END-USER
23.4.1 NORTH AMERICA MARKET BY END-USER
23.4.2 EUROPE MARKET BY END-USER
23.4.3 APAC MARKET BY END-USER
23.4.4 LATIN AMERICA MARKET BY END-USER
23.4.5 MIDDLE EAST & AFRICA MARKET BY END-USER
23.5 MARKET BY GEOGRAPHY
23.5.1 WEARABLES & SENSORS MARKET BY GEOGRAPHY
23.5.2 MOBILE APPLICATION & SOFTWARE MARKET BY GEOGRAPHY
